He is also the director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts.
[5] In 2004, Dr. Kuchroo was promoted to Professor of Neurology at Harvard Medical School and senior scientist at Brigham and Women's Hospital.
[10] Kuchroo initial contribution to the field began with using genetic approaches of transgenesis to generate mouse models for human disease Multiple Sclerosis,[11] a key tool for MS research the world over.
Similar to other checkpoint inhibitors such as PD-1 and CTLA-4, TIM-3 has been successfully targeted to treat several solid and hematogenous malignancies, including melanoma, AML, and MDS.
[13][14][15] Kuchroo was instrumental in shepherding anti-Tim-3 antibody from discovery through to clinic by working with a number of biotech and drug companies to its ultimate use by Novartis for treatment in cancer.
[18][19][20][21] The Kuchroo lab conducted extensive studies characterizing their role in autoimmune disease pathogenesis, and together with Aviv Regev[22][23] at the Broad Institute, built the regulatory network for the development.